Patents Examined by Stephanie W. Zitomer
  • Patent number: 5834193
    Abstract: Methods and compositions for the measurement of telomere length have application in medical diagnostic, prognostic, and therapeutic procedures. The methods for measuring telomere length include primer extension-based methods and probe-based methods. The primer extension methods involve elongation of telomeric, linker, and/or subtelomeric based primers under conditions such that the telomere serves as a template for primer extension and that the resultant primer extension products can be compared to standards of known length to provide a measure of telomere length. The probe based methods allow for telomere length measurements using DNA from lysed or whole cells and involve hybridizing an excess of probe to all telomeric repeat sequences in the telomere, measuring the amount of bound probe, and correlating the amount of bound probe measured with telomere length.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: November 10, 1998
    Assignee: Geron Corporation
    Inventors: Michael R. Kozlowski, Karen R. Prowse, Sy-Shi Wang, Sharon Wong, Nam Woo Kim, Richard Allsopp
  • Patent number: 5830661
    Abstract: Methods of diagnosing glaucoma, and particularly primary congenital glaucoma, by detecting mutations in a gene associated with glaucoma, such as the CYP1B1 gene, are disclosed. Methods include hybridization analysis, such as Southern or Northern analysis, which use hybridization of a mutant nucleic acid probe to the gene associated with glaucoma; direct mutation analysis by restriction digest; sequencing of the gene associated with glaucoma; hybridization of an allele-specific oligonucleotide with amplified genomic DNA; or identification of the presence of mutant proteins encoded by the gene associated with glaucoma. Kits for use in diagnosis of glaucoma are also described. Methods of treatment of glaucoma, including administration of the protein encoded by the gene associated with glaucoma; administration of genes, gene constructs, or other nucleic acid constructs; or administration of other therapeutic agents, are additionally described.
    Type: Grant
    Filed: February 13, 1997
    Date of Patent: November 3, 1998
    Assignee: The University of Connecticut
    Inventor: Mansoor Sarfarazi
  • Patent number: 5830647
    Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocyte progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.
    Type: Grant
    Filed: April 26, 1995
    Date of Patent: November 3, 1998
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Frederic J. de Sauvage
  • Patent number: 5824476
    Abstract: Discrimination between RNAs which differ by as little as a single nucleotide is accomplished by having an excess of unlabeled non-complementary oligonucleotide present during hybridization with a labeled complementary nucleotide. The non-complementary oligonucleotide blocks hybridization of the labeled complementary oligonucleotide sequence without affecting hybridization of the labeled complementary oligonucleotide to the complementary sequence. The label may be an isotope, a fluorescent group or of any other type. The technique permits examination of the transcription of highly related allelic and non-allelic genes present in the same cell and the quantification of such transcripts by use of appropriate internal control. The technique is also useful in oligonucleotide hybridization to DNA sequences which differ only by a single nucleotide.
    Type: Grant
    Filed: February 28, 1996
    Date of Patent: October 20, 1998
    Assignee: City of Hope
    Inventor: R. Bruce Wallace
  • Patent number: 5824787
    Abstract: A polynucleotide marker reagent is described for use in DNA and RNA size determination.
    Type: Grant
    Filed: February 2, 1996
    Date of Patent: October 20, 1998
    Assignee: Gensura Laboratories, Inc.
    Inventor: Paul A. Singer
  • Patent number: 5824518
    Abstract: Methods of synthesizing multiple copies of a target nucleic acid sequence autocatalytically under conditions of substantially constant temperature, ionic strength, and pH are provided in which multiple RNA copies of the target sequence autocatalytically generate additional copies. These methods are useful for generating copies of a nucleic acid target sequence for purposes which include assays to quantitate specific nucleic acid sequences in clinical, environmental, forensic and similar samples, cloning and generating probes.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 20, 1998
    Assignee: Gen-Probe Incorporated
    Inventors: Daniel Louis Kacian, Timothy J. Fultz
  • Patent number: 5821055
    Abstract: Methods and compositions are provided for the production of a polypeptide which is immunologically cross-reactive with a naturally-occurring major outer membrane protein (MOMP) of Chlamydia trachomatis. A DNA construct including a replication system recognized by E. coli, and an MOMP gene under the transcriptional control of a .beta.-galactosidase promoter and terminator is provided.Recombinant phage .lambda.gt11/L2/33 was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, on Jan. 10, 1985 and granted accession no. 40157. L2 B9-F DNA was deposited at the American Type Culture Collection on Dec. 31, 1985, and granted accession No. 40217.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 13, 1998
    Assignees: Washington Research Foundation, Chiron Corporation
    Inventors: Nina Agabian, Richard Stephens, Cho-Chou Kuo, Guy Mullenbach
  • Patent number: 5821058
    Abstract: A process for the electrophoretic analysis of DNA fragments produced in DNA sequencing operations wherein chromophores or fluorophores are used to tag the DNA fragments produced by the sequencing chemistry and permit the detection and characterization of the fragments as they are resolved by electrophoresis through a gel. Preferably four different fragment sets are tagged with the fluorophores fluorescein, Texas Red, tetramethyl rhodamine, and 7-nitrobenzofurazan. A system for the electrophoretic analysis of DNA fragments produced in DNA sequencing operations comprising: a source of chromophore or fluorescent tagged DNA fragments; a zone for contacting an electrophoresis gel; means for introducing said tagged DNA fragments to said zone; and photometric means for monitoring said tagged DNA fragments as they move through said gel.
    Type: Grant
    Filed: December 21, 1994
    Date of Patent: October 13, 1998
    Assignee: California Institute of Technology
    Inventors: Lloyd M. Smith, Leroy E. Hood, Michael W. Hunkapiller, Tim J. Hunkapiller, Charles R. Connell
  • Patent number: 5817785
    Abstract: The present invention includes methods for the identification and production of improved nucleic acid ligands based on the SELEX process. Also included are nucleic acid ligands to the HIV-RT protein identified according to the methods described therein.
    Type: Grant
    Filed: November 13, 1996
    Date of Patent: October 6, 1998
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Larry Gold, Craig Tuerk
  • Patent number: 5814489
    Abstract: A method for producing a contaminating DNA free single stranded PCR amplification product of mRNA is disclosed. The mRNA amplification product is of lower molecular weight and is readily separated, e.g., by gel electrophoresis, from any amplified cellular DNA contaminant.
    Type: Grant
    Filed: August 4, 1995
    Date of Patent: September 29, 1998
    Assignee: City of Hope
    Inventor: Kevin J. Scanlon
  • Patent number: 5814343
    Abstract: A cosmetic composition for topical application to the skin and/or hair includes, optionally in a cosmetically or pharmaceutically acceptable vehicle, particles which enclose a cosmetically-effective benefit agent active at a target location accessible by application to the skin and/or hair, and which have means to bind to an organic surface at the target location. In particular, the particles are liposomes and have means for binding to microorganisms present on the skin and/or hair, for example those responsible for skin disorders, scalp irritation, and underarm and foot odour.
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: September 29, 1998
    Assignee: Unilever Patent Holding B.V.
    Inventors: Malcolm N Jones, Michael Kaszuba, Ian G Lyle
  • Patent number: 5811533
    Abstract: Methods are described for the identification and preparation of nucleic acid ligands to vascular endothelial growth factor (VEGF). Included in the invention are specific RNA ligands to VEGF identified by the SELEX method.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: September 22, 1998
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Larry Gold, Nebojsa Janjic
  • Patent number: 5811237
    Abstract: The invention relates to a sequence of nucleotides, characterized in that it comprises at least a part of a sequence coding for a protein with urease activity such as that expressed by C. pylori.Another subject of the invention is the uses of this sequence, in particular for the in vitro diagnosis of diseases associated with the presence of Campylobacter pylori in the organism of an individual.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 22, 1998
    Assignees: Institut Pasteur, Institut Nationale de la Sante et de la Recherche Medicale
    Inventor: Agnes Labigne
  • Patent number: 5811260
    Abstract: An expression vector for the expression of an exogenous gene in an animal cell, which contains a chick .beta.-actin gene promoter and a restriction enzyme site for incorporating an exogenous gene at the downstream of said promoter and a process for expressing an exogenous gene, which comprises incorporating said exogenous gene into the expression vector at the restriction enzyme site for incorporating the exogenous gene, introducing said vector into an animal cell and culturing the obtained transformed animal cell. The expression system of the present invention can be applied to an expression of any exogenous gene and has an extremely high expression efficiency and is applicable to a wide range of host cells, and hence can sufficiently be utilized for industrial-scale production of a useful material.
    Type: Grant
    Filed: June 23, 1989
    Date of Patent: September 22, 1998
    Assignee: Juridical Foundation The Chemo-Sero Therapeutic Research Institute
    Inventors: Junichi Miyazaki, Ken-ichi Yamamura, Masatake Araki, Hiroshi Yonemura, Chikateru Nozaki
  • Patent number: 5807679
    Abstract: The present invention is a technique which allows one to determine rapidly the nucleic acid sequence of large fragments of nucleic acids such as the inserts obtained from YACs, BACs and Pls. This method uses an array of random primers matched pairwise in all combinations to amplify portions of the fragments to be sequenced. Some of these PCR reactions result in the formation of single bands of amplified DNA which are called islands. These islands are randomly scattered along the fragment of nucleic acid. These individual islands are sequenced, but this leaves major gaps in the complete sequence of DNA. A second round of PCR is performed in which the ends of the islands are used to design primers pointing away from the islands, these primers being matched pairwise in all combinations. This round of PCR again results in some of the reactions forming single bands of amplified nucleic acid. These bands connect the islands determined earlier.
    Type: Grant
    Filed: July 7, 1995
    Date of Patent: September 15, 1998
    Assignee: Myriad Genetics, Inc.
    Inventor: Alexander Kamb
  • Patent number: 5807689
    Abstract: In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 15, 1998
    Assignee: Sibia Neurosciences, Inc.
    Inventors: Lorrie Daggett, Steven B. Ellis, Chen Liaw, Aaron Pontsler, Edwin C. Johnson, Stephen D. Hess
  • Patent number: 5800992
    Abstract: The present invention provides method and apparatus for sequencing, fingerprinting and mapping biological macromolecules, typically biological polymers. The methods make use of a plurality of sequence specific recognition reagents which can also be used for classification of biological samples, and to characterize their sources.
    Type: Grant
    Filed: June 25, 1996
    Date of Patent: September 1, 1998
    Inventors: Stephen P.A. Fodor, Dennis W. Solas, William J. Dower
  • Patent number: 5795721
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to Transcripion Regulatory Factors, specifically ICP4. Included in the invention are specific ssDNA and RNA ligands to ICP4 identified by the SELEX method.
    Type: Grant
    Filed: January 25, 1996
    Date of Patent: August 18, 1998
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Ross S. Rabin, Sumedha D. Jayasena, Larry Gold
  • Patent number: 5792614
    Abstract: A method is disclosed for modifying an oligonucleotide, which method has application to the detection of a polynucleotide analyte. An oligonucleotide is reversibly hybridized with a polynucleotide, for example, a polynucleotide analyte, in the presence of a 5'-nuclease under isothermal conditions. The polynucleotide analyte serves as a recognition element to enable a 5'-nuclease to cleave the oligonucleotide to provide (i) a first fragment that is substantially non-hybridizable to the polynucleotide analyte and (ii) a second fragment that lies 3' of the first fragment (in the intact oligonucleotide) and is substantially hybridizable to the polynucleotide analyte. At least a 100-fold molar excess of the first fragment and/or the second fragment are obtained relative to the molar amount of the polynucleotide analyte. The presence of the first fragment and/or the second fragment is detected, the presence thereof indicating the presence of the polynucleotide analyte.
    Type: Grant
    Filed: August 2, 1996
    Date of Patent: August 11, 1998
    Assignee: Dade Behring Marburg GmbH
    Inventors: Linda M. Western, Samuel J. Rose, Edwin F. Ullman
  • Patent number: 5789157
    Abstract: This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, glioblastomas, and lymphomas are described.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: August 4, 1998
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Kirk B. Jensen, Hang Chen, Kevin N. Morris, Andrew Stephens, Larry Gold